Profile data is unavailable for this security.
About the company
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
- Revenue in USD (TTM)0.00
- Net income in USD-112.90m
- Incorporated2006
- Employees121.00
- LocationAdverum Biotechnologies Inc100 Cardinal WayREDWOOD CITY 94063United StatesUSA
- Phone+1 (650) 649-1004
- Fax+1 (650) 329-8151
- Websitehttps://adverum.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiff Oncology Inc | 610.00k | -40.25m | 158.33m | 31.00 | -- | 2.60 | -- | 259.55 | -0.901 | -0.901 | 0.0137 | 1.36 | 0.0068 | -- | 1.14 | 19,677.42 | -44.55 | -31.24 | -50.10 | -33.56 | -- | -- | -6,594.92 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Vaxart Inc | 8.89m | -81.74m | 158.57m | 109.00 | -- | 2.84 | -- | 17.85 | -0.5431 | -0.5431 | 0.059 | 0.3155 | 0.0813 | -- | 21.67 | 81,513.76 | -74.81 | -49.60 | -86.63 | -54.86 | -- | -- | -920.00 | -1,398.00 | -- | -- | 0.0705 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
| CervoMed Inc | 8.08m | -4.15m | 162.93m | 8.00 | 38.61 | 22.83 | -- | 20.15 | 0.5113 | 0.5113 | 1.74 | 0.8648 | 0.6124 | -- | -- | 1,010,531.00 | -31.45 | -53.67 | -38.42 | -58.89 | -- | -- | -51.36 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Mediwound Ltd | 18.69m | -6.72m | 164.49m | 100.00 | -- | 5.06 | -- | 8.80 | -0.768 | -0.768 | 2.07 | 3.43 | 0.3209 | 6.28 | 2.87 | 186,860.00 | -11.53 | -24.48 | -14.35 | -32.92 | 19.15 | 43.27 | -35.94 | -38.43 | 4.33 | -- | 0.1674 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| Alimera Sciences Inc | 90.22m | -22.66m | 165.50m | 159.00 | -- | 4.07 | -- | 1.83 | -1.57 | -1.57 | 2.42 | 0.7762 | 0.8989 | 7.11 | 3.43 | 567,415.10 | -21.34 | -19.08 | -25.84 | -27.37 | 86.52 | 86.80 | -23.74 | -19.55 | 2.51 | -0.0756 | 0.6323 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
| Rigel Pharmaceuticals Inc | 120.35m | -19.80m | 167.50m | 147.00 | -- | -- | -- | 1.39 | -0.1135 | -0.1135 | 0.69 | -0.1806 | 0.9623 | 0.9241 | 4.23 | 818,680.30 | -15.83 | -28.82 | -30.14 | -47.26 | 93.22 | 97.88 | -16.45 | -35.76 | 1.17 | -2.91 | 2.13 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Greenwich Lifesciences Inc | 0.00 | -8.89m | 168.45m | 3.00 | -- | 25.08 | -- | -- | -0.6921 | -0.6921 | 0.00 | 0.5215 | 0.00 | -- | -- | 0.00 | -86.87 | -36.43 | -89.30 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
| Adverum Biotechnologies Inc | 0.00 | -112.90m | 171.24m | 121.00 | -- | 0.9393 | -- | -- | -10.23 | -10.23 | 0.00 | 8.78 | 0.00 | -- | -- | 0.00 | -41.55 | -36.39 | -47.50 | -39.04 | -- | -- | -- | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Kodiak Sciences Inc | 0.00 | -232.75m | 171.26m | 107.00 | -- | 0.7099 | -- | -- | -4.44 | -4.44 | 0.00 | 4.59 | 0.00 | -- | -- | 0.00 | -43.30 | -31.73 | -47.44 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| P3 Health Partners Inc | 1.35bn | -67.27m | 172.91m | 400.00 | -- | 0.4456 | -- | 0.1278 | -0.5855 | -0.5855 | 11.86 | 1.23 | 1.57 | -- | 11.40 | 3,381,965.00 | -21.31 | -- | -90.11 | -- | 1.59 | 0.1781 | -13.57 | -56.93 | -- | -10.05 | 0.2368 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| Achieve Life Sciences Inc | 0.00 | -27.32m | 173.77m | 22.00 | -- | 3.50 | -- | -- | -1.29 | -1.29 | 0.00 | 1.44 | 0.00 | -- | -- | 0.00 | -60.15 | -86.31 | -109.37 | -119.59 | -- | -- | -- | -- | -- | -9.33 | 0.2574 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| OptiNose Inc | 74.02m | -30.75m | 173.81m | 132.00 | -- | -- | -- | 2.35 | -0.2733 | -0.2733 | 0.659 | -0.8777 | 0.7453 | 0.8764 | 4.74 | 560,772.80 | -30.91 | -48.25 | -- | -98.95 | 88.98 | 86.96 | -41.47 | -131.66 | 2.17 | -1.16 | 4.16 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -18.84m | 178.84m | 1.00 | -- | 59.29 | -- | -- | -0.6889 | -0.6889 | 0.00 | 0.1019 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.8986 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| Lifecore Biomedical Inc | 103.27m | -64.24m | 181.30m | 459.00 | -- | -- | -- | 1.76 | -2.12 | -3.29 | 3.43 | 1.16 | 0.391 | 1.96 | 3.07 | 224,986.90 | -24.32 | -5.67 | -41.13 | -8.07 | 27.10 | 21.91 | -62.20 | -11.90 | 1.35 | -1.05 | 0.7495 | -- | -7.19 | -27.74 | -315.07 | -- | -8.55 | -- |
| Abeona Therapeutics Inc | 3.50m | -76.66m | 183.28m | 84.00 | -- | -- | -- | 52.37 | -3.20 | -3.20 | 0.1461 | -0.3224 | 0.0546 | -- | 2.54 | 41,666.67 | -119.62 | -53.22 | -140.83 | -65.81 | -- | -- | -2,190.26 | -1,894.25 | -- | -- | 1.97 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
Data as of May 20 2024. Currency figures normalised to Adverum Biotechnologies Inc's reporting currency: US Dollar USD
35.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Logos Global Management LPas of 31 Mar 2024 | 1.50m | 7.23% |
| BML Capital Management LLCas of 18 Apr 2024 | 1.05m | 5.06% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 900.53k | 4.34% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 899.51k | 4.33% |
| Franklin Advisers, Inc.as of 31 Mar 2024 | 675.68k | 3.26% |
| Commodore Capital LPas of 31 Mar 2024 | 657.33k | 3.17% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 554.45k | 2.67% |
| Laurion Capital Management LPas of 31 Mar 2024 | 438.94k | 2.12% |
| Avoro Capital Advisor LLCas of 31 Mar 2024 | 416.67k | 2.01% |
| Assenagon Asset Management SA (Germany)as of 31 Mar 2024 | 358.72k | 1.73% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
